Literature DB >> 23997786

Mechanisms of reduced susceptibility to ciprofloxacin in Escherichia coli isolates from Canadian hospitals.

Patricia J Baudry-Simner1, Amanpreet Singh, James A Karlowsky, Daryl J Hoban, George G Zhanel.   

Abstract

OBJECTIVE: To determine whether plasmid-mediated quinolone resistance (PMQR) determinants play a role in the increasing resistance to fluoroquinolones among Escherichia coli isolates in Canadian hospitals, and to determine the mechanisms of reduced susceptibility to ciprofloxacin in a recent collection of 190 clinical E coli isolates.
METHODS: E coli isolates (n=1702) were collected as part of the 2007 Canadian Hospital Ward Antibiotic Resistance Surveillance (CANWARD) study. Antimicrobial susceptibility testing was performed by Clinical and Laboratory Standards Institute (CLSI) broth microdilution. Using a representative subset of isolates (n=190), the mechanisms of reduced susceptibility to ciprofloxacin were detected by polymerase chain reaction and sequencing of the quinolone resistance-determining regions (QRDR) of chromosomal gyrA and parC genes, and by polymerase chain reaction for the PMQR genes: qnr, aac(6') Ib-cr and qepA.
RESULTS: 2.1% and 1.1% of E coli harboured aac(6')Ib-cr and qnrB, respectively. Single amino acid substitutions in the QRDR of gyrA were observed among isolates with ciprofloxacin minimum inhibitory concentrations as low as 0.12 μg/mL. As the ciprofloxacin minimum inhibitory concentration increased to 1 μg/mL (which is still considered to be susceptible by the CLSI), the vast majority of isolates demonstrated both gyrA and parC mutations.
CONCLUSION: PMQR determinants and QRDR mutants among clinical E coli isolates with reduced susceptibility to ciprofloxacin demonstrates the need for increased surveillance and the need to re-evaluate the current CLSI breakpoints to prevent further development of fluoroquinolone resistance.

Entities:  

Keywords:  Ciprofloxacin; Escherichia coli; Fluoroquinolone; Plasmid-mediated quinolone resistance; Quinolone resistance-determining region

Year:  2012        PMID: 23997786      PMCID: PMC3476563          DOI: 10.1155/2012/569093

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


  19 in total

1.  In vivo selection of fluoroquinolone-resistant Escherichia coli isolates expressing plasmid-mediated quinolone resistance and expanded-spectrum beta-lactamase.

Authors:  Laurent Poirel; Johann D D Pitout; Lucy Calvo; Jose-Manuel Rodriguez-Martinez; Deirdre Church; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

2.  Mechanisms of resistance and mobility among multidrug-resistant CTX-M-producing Escherichia coli from Canadian intensive care units: the 1st report of QepA in North America.

Authors:  Patricia J Baudry; Kim Nichol; Melanie DeCorby; Philippe Lagacé-Wiens; Erin Olivier; Dave Boyd; Michael R Mulvey; Daryl J Hoban; George G Zhanel
Journal:  Diagn Microbiol Infect Dis       Date:  2009-03       Impact factor: 2.803

Review 3.  Mechanisms of action and resistance of older and newer fluoroquinolones.

Authors:  D C Hooper
Journal:  Clin Infect Dis       Date:  2000-08       Impact factor: 9.079

4.  Plasmid-mediated quinolone resistance determinants qnr and aac(6')-Ib-cr in Escherichia coli and Klebsiella spp. from Norway and Sweden.

Authors:  Nabil Karah; Laurent Poirel; Stina Bengtsson; Martin Sundqvist; Gunnar Kahlmeter; Patrice Nordmann; Arnfinn Sundsfjord; Ørjan Samuelsen
Journal:  Diagn Microbiol Infect Dis       Date:  2010-04       Impact factor: 2.803

Review 5.  The worldwide emergence of plasmid-mediated quinolone resistance.

Authors:  Ari Robicsek; George A Jacoby; David C Hooper
Journal:  Lancet Infect Dis       Date:  2006-10       Impact factor: 25.071

Review 6.  Mechanisms of resistance to quinolones.

Authors:  George A Jacoby
Journal:  Clin Infect Dis       Date:  2005-07-15       Impact factor: 9.079

7.  Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis.

Authors:  Lindsay Nicolle; Heather Duckworth; Dan Sitar; Lisa Bryski; Godfrey Harding; George Zhanel
Journal:  Int J Antimicrob Agents       Date:  2007-12-26       Impact factor: 5.283

8.  Surveillance for plasmid-mediated quinolone resistance determinants in Enterobacteriaceae within the Calgary Health Region, Canada: the emergence of aac(6')-Ib-cr.

Authors:  Johann D D Pitout; Yi Wei; Deirdre L Church; Daniel B Gregson
Journal:  J Antimicrob Chemother       Date:  2008-02-21       Impact factor: 5.790

Review 9.  Plasmid-mediated quinolone resistance in gram-negative bacterial species: an update.

Authors:  Vincent Cattoir; Patrice Nordmann
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

10.  Is plasmid-mediated quinolone resistance a clinically significant problem?

Authors:  L Poirel; V Cattoir; P Nordmann
Journal:  Clin Microbiol Infect       Date:  2008-01-07       Impact factor: 8.067

View more
  6 in total

Review 1.  SOS response and its regulation on the fluoroquinolone resistance.

Authors:  Ting-Ting Qin; Hai-Quan Kang; Ping Ma; Peng-Peng Li; Lin-Yan Huang; Bing Gu
Journal:  Ann Transl Med       Date:  2015-12

2.  Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones.

Authors:  Muhammad Malik; Arkady Mustaev; Heidi A Schwanz; Gan Luan; Nirali Shah; Lisa M Oppegard; Ernane C de Souza; Hiroshi Hiasa; Xilin Zhao; Robert J Kerns; Karl Drlica
Journal:  Nucleic Acids Res       Date:  2016-03-16       Impact factor: 16.971

3.  Mutation Supply and Relative Fitness Shape the Genotypes of Ciprofloxacin-Resistant Escherichia coli.

Authors:  Douglas L Huseby; Franziska Pietsch; Gerrit Brandis; Linnéa Garoff; Angelica Tegehall; Diarmaid Hughes
Journal:  Mol Biol Evol       Date:  2017-05-01       Impact factor: 16.240

4.  Burden of Fluoroquinolone Resistance in Clinical Isolates of Escherichia coli at the Ho Teaching Hospital, Ghana.

Authors:  John Gameli Deku; Kwabena Obeng Duedu; Emmanuel Ativi; Godsway Edem Kpene; Patrick Kwame Feglo
Journal:  Ethiop J Health Sci       Date:  2022-01

Review 5.  Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties.

Authors:  Sarah C J Jorgensen; Nicholas J Mercuro; Susan L Davis; Michael J Rybak
Journal:  Infect Dis Ther       Date:  2018-03-31

6.  Access to high-impact mutations constrains the evolution of antibiotic resistance in soft agar.

Authors:  Nour Ghaddar; Mona Hashemidahaj; Brandon L Findlay
Journal:  Sci Rep       Date:  2018-11-19       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.